Filtered By:
Source: International Journal of Oncology
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 2365 results found since Jan 2013.
Roles of salt ‑inducible kinases in cancer (Review)
Int J Oncol. 2023 Nov;63(5):118. doi: 10.3892/ijo.2023.5566. Epub 2023 Sep 1.ABSTRACTSalt inducible kinases (SIKs) with three subtypes SIK1, SIK2 and SIK3, belong to the AMP‑activated protein kinase family. They are expressed ubiquitously in humans. Under normal circumstances, SIK1 regulates adrenocortical function in response to high salt or adrenocorticotropic hormone stimulation, SIK2 is involved in cell metabolism, controlling insulin signaling and gluconeogenesis and SIK3 coordinates with the mTOR complex, promoting cancer. The dysregulation of SIKs has been widely detected in various types of cancers. Based on most...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Shenghui Feng Fangyi Wei Haoran Shi Shen Chen Bangqi Wang Deqiang Huang Lingyu Luo Source Type: research
RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity
Int J Oncol. 2023 Nov;63(5):120. doi: 10.3892/ijo.2023.5568. Epub 2023 Sep 1.ABSTRACTRing1 and YY‑1 binding protein (RYBP) is a member of the polycomb repressive complex 1 and serves as a transcriptional suppressor via epigenetic modification. RYBP has a tumour‑suppressive role in solid tumours, but its function in colorectal cancer (CRC) remains unknown. The present study evaluated the expression of RYBP using immunohistochemistry in 140 cases of primary CRC and 11 patient‑matched cases of liver metastases. Using CRC cell lines with different TP53 gene status such as HCT116 (TP53wt/wt), HCT116 (TP53‑/‑), SW48 an...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Takashi Morinaka Nozomu Sakai Tsukasa Takayashiki Satoshi Kuboki Shigetsugu Takano Gaku Ohira Hisahiro Matsubara Masayuki Ohtsuka Source Type: research
Human cytomegalovirus infection enhances 5 ‑lipoxygenase and cycloxygenase‑2 expression in colorectal cancer
Int J Oncol. 2023 Nov;63(5):116. doi: 10.3892/ijo.2023.5564. Epub 2023 Sep 1.ABSTRACTColorectal cancer (CRC) is one of the most common and fatal types of cancer. Inflammation promotes CRC development, however, the underlying etiological factors are unknown. Human cytomegalovirus (HCMV), a virus that induces inflammation and other cancer hallmarks, has been detected in several types of malignancy, including CRC. The present study investigated whether HCMV infection was associated with expression of the pro‑inflammatory enzymes 5‑lipoxygenase (5‑LO) and cyclooxygenase‑2 (COX‑2) and other molecular, genetic and clin...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Mattia Russel Pantalone Nerea Martin Almazan Rossano Lattanzio Chato Taher Simone De Fabritiis Silvia Valentinuzzi Faraz Bishehsari Mahboobeh Mahdavinia Fabio Verginelli Afsar Rahbar Renato Mariani-Costantini Cecilia S öderberg-Naucler Source Type: research
CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia ‑induced invasion and therapeutic resistance
Int J Oncol. 2023 Nov;63(5):117. doi: 10.3892/ijo.2023.5565. Epub 2023 Sep 1.ABSTRACTGlioblastoma (GBM) is the most common and malignant primary brain tumor affecting adults and remains incurable. The mitochondrial coiled‑coil‑helix‑coiled‑coil‑helix domain‑containing protein 2 (CHCHD2) has been demonstrated to mediate mitochondrial respiration, nuclear gene expression and cell migration; however, evidence of this in GBM is lacking. In the present study, it was hypothesized that CHCHD2 may play a functional role in U87 GBM cells expressing the constitutively active epidermal growth factor receptor variant III (...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Jan C Lumibao Payton L Haak Vladimir L Kolossov Jee-Wei Emily Chen Jeremy Stutchman Alejandra Ruiz Mayandi Sivaguru Jann N Sarkaria Brendan A C Harley Andrew J Steelman H Rex Gaskins Source Type: research
Mechanism of multidrug resistance to chemotherapy mediated by P ‑glycoprotein (Review)
Int J Oncol. 2023 Nov;63(5):119. doi: 10.3892/ijo.2023.5567. Epub 2023 Sep 1.ABSTRACTMultidrug resistance (MDR) seriously limits the clinical application of chemotherapy. A mechanism underlying MDR is the overexpression of efflux transporters associated with chemotherapeutic drugs. P‑glycoprotein (P‑gp) is an ATP‑binding cassette (ABC) transporter, which promotes MDR by pumping out chemotherapeutic drugs and reducing their intracellular concentration. To date, overexpression of P‑gp has been detected in various types of chemoresistant cancer and inhibiting P‑gp‑related MDR has been suggested. The present review...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Yichen Tian Yongrong Lei Yani Wang Jiejuan Lai Jianhua Wang Feng Xia Source Type: research
Roles of salt ‑inducible kinases in cancer (Review)
Int J Oncol. 2023 Nov;63(5):118. doi: 10.3892/ijo.2023.5566. Epub 2023 Sep 1.ABSTRACTSalt inducible kinases (SIKs) with three subtypes SIK1, SIK2 and SIK3, belong to the AMP‑activated protein kinase family. They are expressed ubiquitously in humans. Under normal circumstances, SIK1 regulates adrenocortical function in response to high salt or adrenocorticotropic hormone stimulation, SIK2 is involved in cell metabolism, controlling insulin signaling and gluconeogenesis and SIK3 coordinates with the mTOR complex, promoting cancer. The dysregulation of SIKs has been widely detected in various types of cancers. Based on most...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Shenghui Feng Fangyi Wei Haoran Shi Shen Chen Bangqi Wang Deqiang Huang Lingyu Luo Source Type: research
RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity
Int J Oncol. 2023 Nov;63(5):120. doi: 10.3892/ijo.2023.5568. Epub 2023 Sep 1.ABSTRACTRing1 and YY‑1 binding protein (RYBP) is a member of the polycomb repressive complex 1 and serves as a transcriptional suppressor via epigenetic modification. RYBP has a tumour‑suppressive role in solid tumours, but its function in colorectal cancer (CRC) remains unknown. The present study evaluated the expression of RYBP using immunohistochemistry in 140 cases of primary CRC and 11 patient‑matched cases of liver metastases. Using CRC cell lines with different TP53 gene status such as HCT116 (TP53wt/wt), HCT116 (TP53‑/‑), SW48 an...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Takashi Morinaka Nozomu Sakai Tsukasa Takayashiki Satoshi Kuboki Shigetsugu Takano Gaku Ohira Hisahiro Matsubara Masayuki Ohtsuka Source Type: research
Human cytomegalovirus infection enhances 5 ‑lipoxygenase and cycloxygenase‑2 expression in colorectal cancer
Int J Oncol. 2023 Nov;63(5):116. doi: 10.3892/ijo.2023.5564. Epub 2023 Sep 1.ABSTRACTColorectal cancer (CRC) is one of the most common and fatal types of cancer. Inflammation promotes CRC development, however, the underlying etiological factors are unknown. Human cytomegalovirus (HCMV), a virus that induces inflammation and other cancer hallmarks, has been detected in several types of malignancy, including CRC. The present study investigated whether HCMV infection was associated with expression of the pro‑inflammatory enzymes 5‑lipoxygenase (5‑LO) and cyclooxygenase‑2 (COX‑2) and other molecular, genetic and clin...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Mattia Russel Pantalone Nerea Martin Almazan Rossano Lattanzio Chato Taher Simone De Fabritiis Silvia Valentinuzzi Faraz Bishehsari Mahboobeh Mahdavinia Fabio Verginelli Afsar Rahbar Renato Mariani-Costantini Cecilia S öderberg-Naucler Source Type: research
CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia ‑induced invasion and therapeutic resistance
Int J Oncol. 2023 Nov;63(5):117. doi: 10.3892/ijo.2023.5565. Epub 2023 Sep 1.ABSTRACTGlioblastoma (GBM) is the most common and malignant primary brain tumor affecting adults and remains incurable. The mitochondrial coiled‑coil‑helix‑coiled‑coil‑helix domain‑containing protein 2 (CHCHD2) has been demonstrated to mediate mitochondrial respiration, nuclear gene expression and cell migration; however, evidence of this in GBM is lacking. In the present study, it was hypothesized that CHCHD2 may play a functional role in U87 GBM cells expressing the constitutively active epidermal growth factor receptor variant III (...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Jan C Lumibao Payton L Haak Vladimir L Kolossov Jee-Wei Emily Chen Jeremy Stutchman Alejandra Ruiz Mayandi Sivaguru Jann N Sarkaria Brendan A C Harley Andrew J Steelman H Rex Gaskins Source Type: research
Mechanism of multidrug resistance to chemotherapy mediated by P ‑glycoprotein (Review)
Int J Oncol. 2023 Nov;63(5):119. doi: 10.3892/ijo.2023.5567. Epub 2023 Sep 1.ABSTRACTMultidrug resistance (MDR) seriously limits the clinical application of chemotherapy. A mechanism underlying MDR is the overexpression of efflux transporters associated with chemotherapeutic drugs. P‑glycoprotein (P‑gp) is an ATP‑binding cassette (ABC) transporter, which promotes MDR by pumping out chemotherapeutic drugs and reducing their intracellular concentration. To date, overexpression of P‑gp has been detected in various types of chemoresistant cancer and inhibiting P‑gp‑related MDR has been suggested. The present review...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Yichen Tian Yongrong Lei Yani Wang Jiejuan Lai Jianhua Wang Feng Xia Source Type: research
Roles of salt ‑inducible kinases in cancer (Review)
Int J Oncol. 2023 Nov;63(5):118. doi: 10.3892/ijo.2023.5566. Epub 2023 Sep 1.ABSTRACTSalt inducible kinases (SIKs) with three subtypes SIK1, SIK2 and SIK3, belong to the AMP‑activated protein kinase family. They are expressed ubiquitously in humans. Under normal circumstances, SIK1 regulates adrenocortical function in response to high salt or adrenocorticotropic hormone stimulation, SIK2 is involved in cell metabolism, controlling insulin signaling and gluconeogenesis and SIK3 coordinates with the mTOR complex, promoting cancer. The dysregulation of SIKs has been widely detected in various types of cancers. Based on most...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Shenghui Feng Fangyi Wei Haoran Shi Shen Chen Bangqi Wang Deqiang Huang Lingyu Luo Source Type: research
RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity
Int J Oncol. 2023 Nov;63(5):120. doi: 10.3892/ijo.2023.5568. Epub 2023 Sep 1.ABSTRACTRing1 and YY‑1 binding protein (RYBP) is a member of the polycomb repressive complex 1 and serves as a transcriptional suppressor via epigenetic modification. RYBP has a tumour‑suppressive role in solid tumours, but its function in colorectal cancer (CRC) remains unknown. The present study evaluated the expression of RYBP using immunohistochemistry in 140 cases of primary CRC and 11 patient‑matched cases of liver metastases. Using CRC cell lines with different TP53 gene status such as HCT116 (TP53wt/wt), HCT116 (TP53‑/‑), SW48 an...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Takashi Morinaka Nozomu Sakai Tsukasa Takayashiki Satoshi Kuboki Shigetsugu Takano Gaku Ohira Hisahiro Matsubara Masayuki Ohtsuka Source Type: research
Human cytomegalovirus infection enhances 5 ‑lipoxygenase and cycloxygenase‑2 expression in colorectal cancer
Int J Oncol. 2023 Nov;63(5):116. doi: 10.3892/ijo.2023.5564. Epub 2023 Sep 1.ABSTRACTColorectal cancer (CRC) is one of the most common and fatal types of cancer. Inflammation promotes CRC development, however, the underlying etiological factors are unknown. Human cytomegalovirus (HCMV), a virus that induces inflammation and other cancer hallmarks, has been detected in several types of malignancy, including CRC. The present study investigated whether HCMV infection was associated with expression of the pro‑inflammatory enzymes 5‑lipoxygenase (5‑LO) and cyclooxygenase‑2 (COX‑2) and other molecular, genetic and clin...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Mattia Russel Pantalone Nerea Martin Almazan Rossano Lattanzio Chato Taher Simone De Fabritiis Silvia Valentinuzzi Faraz Bishehsari Mahboobeh Mahdavinia Fabio Verginelli Afsar Rahbar Renato Mariani-Costantini Cecilia S öderberg-Naucler Source Type: research
CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia ‑induced invasion and therapeutic resistance
Int J Oncol. 2023 Nov;63(5):117. doi: 10.3892/ijo.2023.5565. Epub 2023 Sep 1.ABSTRACTGlioblastoma (GBM) is the most common and malignant primary brain tumor affecting adults and remains incurable. The mitochondrial coiled‑coil‑helix‑coiled‑coil‑helix domain‑containing protein 2 (CHCHD2) has been demonstrated to mediate mitochondrial respiration, nuclear gene expression and cell migration; however, evidence of this in GBM is lacking. In the present study, it was hypothesized that CHCHD2 may play a functional role in U87 GBM cells expressing the constitutively active epidermal growth factor receptor variant III (...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Jan C Lumibao Payton L Haak Vladimir L Kolossov Jee-Wei Emily Chen Jeremy Stutchman Alejandra Ruiz Mayandi Sivaguru Jann N Sarkaria Brendan A C Harley Andrew J Steelman H Rex Gaskins Source Type: research
Mechanism of multidrug resistance to chemotherapy mediated by P ‑glycoprotein (Review)
Int J Oncol. 2023 Nov;63(5):119. doi: 10.3892/ijo.2023.5567. Epub 2023 Sep 1.ABSTRACTMultidrug resistance (MDR) seriously limits the clinical application of chemotherapy. A mechanism underlying MDR is the overexpression of efflux transporters associated with chemotherapeutic drugs. P‑glycoprotein (P‑gp) is an ATP‑binding cassette (ABC) transporter, which promotes MDR by pumping out chemotherapeutic drugs and reducing their intracellular concentration. To date, overexpression of P‑gp has been detected in various types of chemoresistant cancer and inhibiting P‑gp‑related MDR has been suggested. The present review...
Source: International Journal of Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Yichen Tian Yongrong Lei Yani Wang Jiejuan Lai Jianhua Wang Feng Xia Source Type: research
